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INTRODUCTION
Successful transplantation of allogeneic hematopoietic
stem cells (HSC) requires that two immunologic barriers be
overcome. The first, a host-vs.-graft (HVG) reaction, leads
to graft rejection. The second, a graft-vs.-host (GVH) reac-
tion, leads to an immunologic attack on the graft recipient.
Traditional approaches to controlling these two reactions
have followed distinctly different principles. Control of
HVG reactions has been achieved through the use of regi-
mens delivered before transplant, with the goal of complete-
ly eradicating the host’s immune responses. To accomplish
this, high-dose conditioning therapy has been given, which
also has the purpose of eliminating the patient’s underlying
disease (e.g., leukemia). Attempts to reduce the risk of graft
rejection have included intensification of conditioning regi-
mens and addition of antibodies targeting T cells. The
intensity and relative lack of specificity of conditioning regi-
mens results in almost complete destruction of any vestiges
of the patient’s normal hematopoietic system. Acute and
profound pancytopenia ensues, and the immediate role of
the subsequent stem cell graft is to promptly restore
hematopoiesis. Control of the GVH reactions involves tar-
geting donor cells through agents delivered after transplant
or through removal of T cells from the graft. Given the
fragility of the transplanted HSC graft and the need for
rapid engraftment, postgrafting immunosuppression must
be minimally myelosuppressive and, ideally, would affect
only those donor cells that mediate the GVH reaction.
In attempts to achieve therapeutic goals (eradication of
malignancy and prevention of graft rejection), conditioning
regimens have been intensified such that dose-limiting toxi-
cities are frequently incurred. Profound pancytopenia pre-
disposes to the development of serious and potentially fatal
infections. Therapy-related organ toxicities, particularly
those affecting liver, kidneys, and gastrointestinal tract, can
impair adequate delivery of postgrafting agents such as
cyclosporine and methotrexate given to control GVHD.
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ABSTRACT
Traditional approaches to allogeneic stem cell transplantation have relied on the use of toxic high-dose conditioning
therapy to achieve allogeneic engraftment and control of underlying disease. Preclinical studies and clinical observa-
tions have shown that, for engraftment purposes, conditioning regimens can be reduced in intensity, resulting in
reduced treatment toxicities. In preclinical canine studies, the use of potent pre- and postgrafting immunosuppres-
sion allowed for reduction in conditioning regimens and development of stable mixed chimerism. If these newer
approaches using attenuated conditioning regimens can be successfully applied to human transplantation, an
improved safety profile will allow potentially curative treatment of patients not currently offered such therapy.
Mixed chimerism per se could prove curative of disease manifestation for various nonmalignant disturbances of the
hematopoietic and immune systems. For patients with malignancy, infusion of additional donor lymphocytes may be
needed to effectively treat underlying disease. 
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The inability of older patients to tolerate these combined
insults has restricted the use of HSC allografting to relative-
ly young patients who can better tolerate intensive therapy.
To manage the side effects of HSCT, it has traditionally
been delivered in highly specialized hospital wards. 
An important goal is to develop safer approaches to allo-
grafting that can also be extended to older patients or patients
with preexisting organ toxicities that preclude the use of
high-dose conditioning regimens. Implicit in these aims is
that treatment of the underlying diseases would not depend
on the use of nonspecific high-dose myeloablative chemora-
diotherapy, but rather on disease-specific targeting mediated
by alloreactive immune cells, possibly in combination with
other cell-directed targeting of the malignancy, such as
monoclonal antibodies recognizing cell-surface antigens.
Several important observations from HSC allografting
relevant to this goal have emerged over the years. First,
advanced hematologic malignancies are rarely cured using
even the most intensive conditioning regimens, echoing
observations in the 1960s by Burchenal et al. [1] that murine
leukemia could be eradicated only through the use of total-
body irradiation (TBI) doses of several thousand centigray,
which would be incompatible with human survival after
transplant. Second, beyond rescuing patients from hemato-
poietic toxicity, allografts provide a graft-vs.-leukemia
(GVL) effect, which has been responsible for many observed
cures, particularly in patients with advanced leukemias. This
was predicted from murine studies reported by Barnes et al.
[2] and for which Mathé et al. [3] later coined the term
“adoptive immunotherapy.” GVL effects in humans were
first described by Weiden and colleagues in 1979 and 1981
[4,5]. Their observations were subsequently confirmed by
others [6–10] and led to the testing of donor buffy coat infu-
sions to augment GVL activity of marrow allografts [11] and
subsequently to the use of donor lymphocyte infusions
(DLI) as a treatment for patients whose malignancy had
relapsed after allografting [12–16]. Complete clearing of
malignant and nonmalignant host hematopoiesis through
alloimmune reactions supports the concept that grafts can
create their own marrow space without need for myelosup-
pressive conditioning therapy. Third, in a small number of
patients transplanted for either thalassemia major or sickle
cell disease, stable mixed chimerism has been observed and
found to result in the resolution of clinical manifestations of
disease [17,18]. Fourth, in transplants from major histocom-
patibility complex (MHC)-identical donors, both HVG and
GVH reactions are mediated by T cells, a fact that stimulat-
ed studies on whether postgrafting immunosuppression
designed to prevent GVHD could also be used to suppress
host immunity and thereby enhance allogeneic engraftment.
These observations have provided underlying principles for
the development of novel, safer transplant protocols that can
be carried out in an ambulatory care setting and extended to
older patients or those with organ toxicities that would oth-
erwise preclude allogeneic transplantation.
MIXED CHIMERISM IN HUMANS
Prior observations
Mixed chimerism was first described in leukemia
patients who received cyclophosphamide-based regimens
before allogeneic HSC transplantation [19]. In patients with
aplastic anemia conditioned only with high doses of
cyclophosphamide before marrow allografting from HLA-
identical sibling donors, mixed donor-host chimerism was
found in a substantial proportion of patients and was associ-
ated with less risk of GVHD than in patients who were
complete donor chimeras [20,21]. Branch et al. [22] and
Petz et al. [23] reported finding mixed chimerism in patients
transplanted for hematologic malignancies using unmodified
bone marrow grafts after myeloablative therapy. This find-
ing did not predict subsequent risk of disease relapse,
although others have made an association between mixed
chimerism and relapse risk. 
Mixed chimerism has been found most frequently in
patients who either received T cell–depleted marrow grafts
or underwent transplants for genetic diseases and received
unmodified grafts. Depletion of T cells from the graft has
also been associated with an increased risk of graft rejection
and risk of disease relapse with these outcomes [24,25]. A
period of unstable mixed chimerism most likely precedes the
adverse event. In contrast, transplantation of CD6-depleted
marrow after high-dose conditioning regimens for hemato-
logic malignancy resulted in stable mixed chimerism in
~51% of patients and was associated with protection from
GVHD and relapse [26]. In other reports, stable mixed
chimerism after marrow allografting has been associated with
clinical benefit in patients with b-thalassemia, sickle cell dis-
ease, mucopolysaccharidosis, and immunodeficiency diseases.
Observations of so-called microchimerism have been
made in solid organ transplant recipients, raising the ques-
tion of whether microchimerism contributes to survival of
the organ graft [27–29]. Although it might be anticipated
that a patient with mixed chimerism induced by marrow
allografting would accept a donor solid organ without rejec-
tion, it is not yet clear whether the microchimerism
observed after solid organ transplants represents an epiphe-
nomenon as a result of patient immunosuppression or is
indeed a factor in long-term graft survival. A number of
studies are ongoing to determine whether the administra-
tion of donor bone marrow in conjunction with organ grafts
can enhance graft survival. These objectives are supported
by findings in mice and later in dogs that irradiation
chimeras tolerate organ transplants from their HSC donors
without the need for prolonged immunosuppression. 
Potential clinical applications
Stable mixed hematopoietic chimerism implies a state of
mutual donor–host tolerance and, thus, control of GVH and
HVG reactions. Ideally, this state would be associated with
normal immune responses against other antigens. Develop-
ment of successful strategies for establishing stable mixed
chimerism without need for continued use of immunosup-
pressive agents would have important therapeutic implica-
tions for a number of diseases. To be clinically useful for
some diseases, such as thalassemia, a substantial donor com-
ponent of hematopoiesis may be required to alleviate clinical
symptoms. In some settings, such as autoimmune disease or
organ transplants, it has been speculated that low levels of
stable donor chimerism may be adequate to achieve the clin-
ical goals of controlling autoreactivity and preventing graft
rejection, respectively. In patients with malignancy, it is like-
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ly that conversion of mixed chimerism to full donor
chimerism would be necessary to treat malignancy and pre-
vent disease recurrence. Table 1 summarizes some potential
applications of mixed chimerism for the treatment of disease
in humans. To be clinically useful and acceptable to patients
in many of the clinical situations suggested, mixed
chimerism would need to be established with minimal toxic-
ity to the patient. Thus developing nontoxic, nonmyelosup-
pressive regimens that can be readily applied in an outpa-
tient setting should be the goal of new strategies to establish
mixed chimerism in humans. An alternative, the establish-
ment of full donor chimerism with minimally toxic
immunosuppressive regimens, would also represent a major
advance in allografting for some diseases.
ASSESSMENT OF HEMATOPOIETIC CHIMERISM
For practical purposes, mixed hematopoietic chimerism
can be defined as the detection of 2.5–97.5% cells of donor
origin in hematopoietic tissues, which approximately defines
the sensitivity of routinely used assays for quantitating
chimerism. Quantitation depends on identifying and meas-
uring genetic markers that differ between the donor and the
graft recipient. Conventional cytogenetic analysis has limit-
ed sensitivity due to the analysis of only a small number of
dividing cells. Fluorescent in situ hybridization (FISH) with
X and Y chromosome–specific probes evaluates all nucleated
cells whether arresting or dividing and, thus, allows the
study of a larger number of cells in the setting of a sex-mis-
matched transplant. Polymerase chain reaction (PCR)-based
assays of polymorphic mini- or microsatellite markers pro-
vide a quantitation of chimerism in sex-matched and -mis-
matched transplant settings. The detection of
microchimerism (<2.5% of donor cells) requires the use of
more sensitive assays than those routinely employed to
detect Y chromosome sequences in male cells transplanted
into the female recipient. In transplants for malignancy,
tumor-specific markers may be evaluated by sensitive tech-
niques such as PCR to detect persistence of host cells
derived from the underlying malignancy.
Additional information may be obtained through the
use of fluorescence-activated cell sorting (FACS) to isolate
specific cell populations that can then be evaluated using
the above techniques. In transplants to establish mixed
chimerism, assays performed on T cells and other pheno-
typically defined cell populations may prove informative in
evaluating clinical outcomes. Because T cells are the criti-
cal cell population mediating HVG and GVH reactions,
monitoring T cell chimerism is an important aspect of
evaluating the immunologic status of the individual. This
may be especially important when admixtures of malignant
cells coexist with normal cell populations as demonstrated
in Figure 1.
ESTABLISHING MIXED CHIMERISM IN EXPERIMENTAL
MODELS
Rodent studies
A number of investigators have reported establishing
mixed chimerism in mice using regimens of less intensity
than those conventionally used to establish allografts. In a
number of these studies, in vivo T cell depletion using
monoclonal antibodies has been combined with TBI at
doses that, at least in mice, were sublethal. In other reports,
sublethal TBI was given along with thymic irradiation and
postgrafting cyclosporine or high-dose cyclophosphamide.
In a study reported by Cobbold et al. [30], pretransplant
treatment with monoclonal antibodies against CD4 and
CD8 was combined with 600–850 cGy TBI given at 35
cGy/min. In another report, nonobese diabetic (NOD) mice
were conditioned for transplant with ‡ 750 cGy TBI fol-
lowed by infusion of large numbers of allogeneic bone mar-
row cells (>1.53109/kg) [31]. In another report, mice were
successfully conditioned for transplant with 500 cGy TBI
and 200 mg/kg cyclophosphamide given after transplanta-
tion. Other investigators combined monoclonal antibodies
against CD4 and CD8 with 300 cGy TBI and 700 cGy
thymic irradiation to achieve engraftment [32]. They further
reported that thymic irradiation could be omitted by using
injections of monoclonal antibodies against CD4 and CD8
after transplant [33,34]. Subsequently, mixed chimerism was
achieved through pretreatment with the same monoclonal
antibodies, thymic irradiation, and the injection of large
doses of marrow cells (8.73109/kg) [35]. In another study,
sustained mixed chimerism for up to 16 weeks posttrans-
plant was achieved after recipients were given monoclonal
antibodies to CD4 and CD8 combined with 300 cGy TBI
administered at 100 cGy/min before transplant, followed by
monoclonal antibodies against natural killer cells for 16
weeks posttransplant [36]. It has been reported that a novel
CD3+, CD8+, T cell receptor (TCR) ab–, TCR gd–, CD8+
lymphocyte population can enhance allogeneic engraftment
after less than optimal immunosuppression [37]. 
Seledtsov et al. [38] used 200 mg/kg cyclophosphamide
to condition mice with p815 leukemia to achieve mixed
chimerism and prolonged recipient survival compared with
syngeneic controls. Koch and Korngold [39] established sus-
tained chimerism in MHC-mismatched murine allograft
recipients after pretreatment with a synthetic-based CD4-
CDR3 peptide analog combined with TBI. Mixed chimerism
has also been reported in mice given allogeneic marrow,
Table 1. Potential clinical applications of mixed chimerism
Disease Goal
Hemoglobinopathies Correction of anemia, iron overload
Genetically based Provide normal lymphocyte function
immunodeficiency and 
enzyme deficiency
Malignancy Eradicate disease using adoptive immunotherapy
Organ transplantation Tolerance of organ graft without prolonged 
immunosuppressive therapy
HIV infection Restore lymphocyte numbers and function; 
boosts from donor as needed; eradicate virus-
containing host cells
Autoimmune diseases Control autoreactivity using donor immunity or 
subsequent adoptive immunotherapy to 
eradicate autoreactive host lymphocytes
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FK506, and treatment with granulocyte-macrophage colony-
stimulating factor (GM-CSF) or flt3-ligand [40]. 
In general, it is difficult to translate the rodent findings
directly to humans. Engraftment across MHC barriers in
mice has not been predictive for humans, appears to be
more readily achieved, and is associated with less GVHD
than observed in the human setting. Most of the regimens
used in the rodents are too intensive for the goal of estab-
lishing mixed chimerism in humans with minimally toxic
therapy. 
Primate studies
There are several reports of attempts to establish mixed
chimerism in conjunction with organ grafting across MHC
barriers in primates. In one study, cynomolgus monkeys
were pretreated with antithymocyte globulin (ATG), 300
cGy TBI, and 700 cGy thymic irradiation with postgrafting
cyclosporine for 4 weeks [41]. Marrow chimerism persisted
for 18–51 days posttransplant with maximum levels ranging
from 1.5 to 57.8%. Of note, kidney grafts persisted for
extended periods of time without immunosuppression
Figure 1. Fractionation of peripheral blood for chimerism analysis by cell sorting in a patient with chronic lymphocytic leukemia
A. Flow cytometry profiles of peripheral blood cell populations isolated for chimerism analysis by FISH to detect X and Y chromosomes. R1 is the mononuclear cell
gate from which cells expressing CD3 (R2 ) or CD19 (R3 ) were isolated by cell sorting. B. Percent of donor cells in peripheral blood. Whereas unfractionated
PBMC are 15% donor, T cells and granulocytes are 98 and 99% donor, respectively. Although mixed chimerism resulted from a large admixture of host B cells,
the development of GVHD at this time was consistent with high-level donor engraftment in the T cell and granulocyte compartments.
P.A. McSweeney and R. Storb
196
despite the fact that the marrow grafts had been rejected. In
subsequent studies, a TBI dose of 250 cGy was less success-
ful and the addition of deoxyspergualin to TBI was not
effective [42]. In a study by Thomas et al. [43], the use of
peritransplant anti-CD3 immunotoxin combined with bone
marrow depleted of mature antigen-presenting cells was
associated with persistence of mixed chimerism in two of six
rhesus monkeys studied and with microchimerism in two of
three additional animals for periods ranging between 6 and
16 weeks posttransplant. This was associated with survival of
kidney grafts for periods between 120 days and >1.5 years. 
Canine studies
A significant proportion of this review focuses on canine
preclinical studies because of important recent observations
that are relevant to current human clinical studies. Distinct
advantages of the dog model over other large animal models
are the availability of MHC typing for determination of
MHC relationships between potential littermate donors and
the ready availability of dog leukocyte antigen (DLA)-iden-
tical littermates as a model for HLA-identical transplants in
humans. The following section describes transplants
between healthy, randomly bred dogs using DLA-identical
marrow grafts. The focus was on establishing engraftment
across minor histocompatibility barriers through immuno-
suppression specifically targeting host and donor T cells.
TBI has been an integral part of these studies, and it has an
important role in the development of nonmyeloablative
transplant approaches because of important immunosup-
pressive properties. 
Marrow toxicity of TBI [44]. TBI delivered in a single
fraction at 7 cGy/min in dogs subsequently given intensive
supportive care but no HSC grafts causes lethal marrow fail-
ure at ‡ 400 cGy. After 300 cGy, approximately two-thirds of
dogs die; after 200 cGy, endogenous marrow recovery usual-
ly occurs (only one of 19 animals died); and after 100 cGy,
all 12 dogs studied survived. Thus a dose of 200 cGy should
pose little risk of irreversible marrow failure should graft
rejection occur.
Immunosuppressive properties of TBI. Results of unmodi-
fied marrow grafting given without postgrafting immuno-
suppression after conditioning therapy with various doses of
TBI are shown in Table 2 [45,46]. A dose of 920 cGy was
sufficiently immunosuppressive to allow stable engraftment
in 95% of dogs transplanted. With reduced doses of TBI,
the frequency of sustained engraftment dropped. At 450
cGy, only 41% of dogs had stable engraftment as mixed or
full donor chimeras, whereas most dogs rejected their grafts
and either died with marrow aplasia (23%) or survived with
eventual autologous recovery (36%). Transient hemato-
poietic support provided by the allograft accounts for autol-
ogous recovery seen in some dogs that received otherwise
lethal TBI. 
Engraftment is facilitated by postgrafting immunosuppressive
drug therapy [47]. In these experiments, immunosuppressive
agents were discontinued by 35 days after transplant. At 450
cGy TBI, cyclosporine and prednisone, two drugs common-
ly used in GVHD prevention, were tested for enhancing
engraftment. Cyclosporine was given orally at 15 mg/kg
b.i.d. starting on day –1 and continued through day 35.
Prednisone was given at 12.5 mg/kg orally b.i.d. on days –5
to 3 with tapering through day 32. The prednisone regimen
was designed based on studies that used high-dose chemo-
therapy as part of conditioning for second marrow grafts
[48,49]. All seven cyclosporine recipients had stable engraft-
ment without GVHD, significantly better than six of 17
dogs that did not receive cyclosporine (p = 0.01) and consis-
tent with a hypothesis that postgrafting immunosuppression
could control HVG reactions. High-dose prednisone did
not enhance engraftment: none of the five transplanted dogs
had sustained allogeneic engraftment.
After 200 cGy TBI, cyclosporine alone failed to estab-
lish stable grafts (Table 2), and four dogs had endogenous
hematopoietic recovery after early graft rejection. Cyclo-
sporine was then combined with methotrexate, a drug
shown to be synergistic with cyclosporine in preventing
GVHD in dogs and humans. Two of five evaluable dogs
became stable mixed chimeras, whereas three rejected their
grafts. Mycophenolate mofetil (MMF), an antimetabolite
that blocks de novo purine synthesis, was then tested in
combination with cyclosporine. In studies of GVHD pre-
vention, a combination of MMF and cyclosporine appeared
synergistic and was superior to methotrexate/cyclosporine
[50]. With the use of MMF/cyclosporine after 200 cGy
TBI, 10 of 11 dogs became stable mixed chimeras for up to
130 weeks posttransplant (Table 2). GVHD was not
observed in these dogs. Thus, dual-agent postgrafting
immunosuppression with MMF/cyclosporine allowed a
reduction of 720 cGy in the TBI dose needed to achieve
sustained allogeneic engraftment. The contribution of
donor cells to hematopoiesis ranged from 45 to 85%, and
donor chimerism was usually higher in myeloid cells than in
lymphocytes or lymph nodes. Based on peripheral blood
CD4/CD8 ratios, the humoral responses to sheep red blood
cells, and in vitro studies of lymphocyte responsiveness to
concanavalin A and to alloantigens, immune function of the
stable mixed chimeras appeared to be in the normal range.
Skin grafts from the marrow donors were accepted but
third-party skin grafts were rejected, indicating specific tol-
Table 2. Effect of TBI dose and postgrafting immunosuppression on 
engraftment of DLA-identical marrow grafts
TBI dose Postgrafting Dogs with stable 
(cGy) immunosuppression engraftment*/Total transplants
920 None 20/21
450 None 6/17
450 Cyclosporine* 7/7
450 Prednisone† 0/5
200 Cyclosporine* 0/4
200 Methotrexate‡/cyclosporine* 2/5
200 MMF§/cyclosporine* 11/12
100 MMF§/cyclosporine* 0/6
*Mixed or full donor chimerism.
*Cyclosporine 15 mg/kg p.o. b.i.d. days –1 to 35.
†Prednisone 12.5 mg/kg p.o. days –5 to –3 with tapering to day 32.
‡Methotrexate 0.4 mg/kg i.v. days 1,3, 6, and 11.
§Mycophenolate mofetil 10 mg/kg b.i.d. s.c. days 0–27.
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erance to donor cells. Figure 2 shows the peripheral blood
counts and microsatellite marker studies from one of these
dogs to illustrate the transplant procedure. Persistence of
donor- and host-specific bands in marrow, peripheral blood,
and lymph node cells was evidence of stable mixed
chimerism after transplant.
After 100 cGy TBI, MMF/cyclosporine did not allow
for the establishment of stable mixed chimerism [47]. How-
ever, when granulocyte colony-stimulating factor (G-CSF)-
mobilized peripheral blood stem cells (PBSC) were used,
stable mixed chimerism was observed in two of five dogs,
and in the others that rejected, longer graft survival was
observed than in dogs that rejected bone marrow transplants
[51]. Studies in other transplant settings have demonstrated
an engraftment-enhancing property of unmodified PBSC
[52], and along with these results, suggest that PBSC facili-
tate engraftment with less immunosuppression than bone
marrow grafts. 
Mechanism of low-dose TBI: Host immunosuppression or cre-
ating marrow space? An established concept has been that
regimens administered before transplant are necessary to
create marrow space in which the incoming graft can settle.
To address the role of TBI in establishing mixed chimerism,
six dogs were given marrow grafts and postgrafting
Figure 2. Establishment of stable mixed chimerism after nonmyeloablative conditioning
A. Platelet and neutrophil counts after 200 cGy TBI, a marrow graft from a DLA-identical sibling on day 0, and postgrafting MMF/cyclosporine to 5 weeks post-
transplant. B. Microsatellite marker analysis by PCR showing pretransplant samples (left) and recipient cells after transplantation (right). DSB, donor specific
band; RSB, recipient specific band; PBWC, unfractionated peripheral blood white cells.
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MMF/cyclosporine after 450 cGy irradiation (at 200
cGy/min) given to cervical, thoracic, and upper abdominal
lymph nodes while at the same time shielding marrow-con-
taining bones with lead blocks [53]. Each dog showed evi-
dence of initial mixed chimerism. Whereas myelosuppres-
sion was minimal, with granulocyte nadirs of 3500/µL and
platelet nadirs >100,000/µL, profound lymphocytopenia
ensued, with nadirs ~200/µL and slow recovery. Two dogs
rejected their grafts by weeks 8 and 18, respectively; one dog
died with allogeneic engraftment from GVHD; and three
remained stable mixed chimeras with follow-up of 38–90
weeks. Marrow samples from unirradiated bones showed
mixed chimerism from as early as 4 weeks posttransplant
and persisting for the period of observation. These results
support the hypothesis that marrow grafts can create their
own marrow space, most likely through a mechanism of
subclinical GVH reactions, and suggest that engraftment
can be achieved across minor histocompatibility barriers,
specifically through suppression of host T cells. Thus, TBI
may be replaced by the use of other immunosuppressive
agents such as monoclonal antibodies to CD3 or TCR, and
using molecules to target costimulation reactions,such as
CTLA4, CD154 (CD40 ligand).
Mixed chimerism in a model of severe hereditary hemolytic
anemia. Severe canine hereditary hemolytic anemia due to
pyruvate kinase (PK) deficiency can be considered a model
for genetically determined hemolytic anemia in humans.
HSC transplants from healthy littermates after high-dose
conditioning corrected hemolytic anemia and led to resolu-
tion of preexisting severe hepatic iron overload [54], find-
ings that encouraged HSC transplantation as a treatment for
b-thalassemia. Using the canine PK deficiency model, stud-
ies were initiated to test the hypothesis that establishing
mixed chimerism can correct the phenotypic manifestations
of a genetic disease. Support for the hypothesis has come
from an initial transplant of a 5-year-old Basenji dog with
PK deficiency. Immediately pretransplant, the dog had a
hematocrit of 24% with a reticulocyte count of 30%. Pre-
transplant biopsies of liver and marrow showed extensive
hemosiderosis and fibrosis along with extramedullary hepat-
ic hematopoiesis. After 200 cGy TBI before and
MMF/cyclosporine after marrow transplant from a healthy
DLA-identical littermate, mixed chimerism was established
without GVHD and resulted in improvement of the hemat-
ocrit to 44% and the reticulocyte count to 1.2%. Engraft-
ment was evident at 3 weeks posttransplant, and mixed
chimerism stabilized, with blood and marrow showing 80%
donor cells. Longer follow-up will determine whether pre-
existing hemosiderosis and extramedullary hematopoiesis
resolve in the setting of mixed chimerism.
THERAPEUTIC APPLICATION OF MIXED CHIMERISM
Conceptual basis
To date, only a few reports document a specific goal of
establishing stable mixed hematopoietic chimerism in patients
with hematologic diseases. The safety and efficacy of the
canine preclinical studies helped develop a hypothetical con-
ceptual schema for studies pertaining to the clinical applica-
tion of mixed chimerism (Fig. 3). Because the use of cytotoxic
agents does not appear to be necessary to create marrow
space, in patients with profound T cell deficiencies a condi-
tioning regimen may not be required before HSC transplant,
and postgrafting immunosuppression may suffice. Immuno-
competent patients would require treatment with an
immunosuppressive, but not myelosuppressive, regimen
before transplant. After transplantation all patients would
receive immunosuppression, for instance MMF/cyclosporine,
to prevent both rejection and GVHD. In the absence of mye-
loablation, host hematopoietic cells would survive in various
proportions along with the engrafted donor cells, resulting in
stable mixed chimerism. An adequate percentage of donor
cells in the mixture, such as 20–30%, would be expected to
correct phenotypic manifestations of most genetic hemato-
logic diseases as suggested by observations of mixed
chimerism in allograft recipients with thalassemia major [17]
and sickle cell disease [18]. If the clinical response of the non-
malignant disease to mixed chimerism was inadequate, com-
plete chimerism could be achieved through DLI (Fig. 3). The
successful use of DLI has already been described in a patient
with b-thalassemia [55]. 
For the treatment of malignant diseases, mixed
chimerism per se would not be expected to be effective in
preventing relapse. Thus, DLI would be required after ini-
tial engraftment to convert mixed to complete donor
chimerism and to treat any persisting host malignancy. In
some cases, the establishment of all-donor hematopoiesis
may occur with the initial transplant, thus obviating the
need for DLI. Some degree of effectiveness of DLI in eradi-
cating recurrent malignancy after conventional transplanta-
tion has been demonstrated for most hematologic malignan-
cies, but DLI is most potent against chronic myeloid
leukemia. For application to treatment of solid tumors,
innovative approaches to targeting the malignancy will be
required. Strategies to develop more effective, safer
approaches to DLI are being tested. These include the
insertion of a suicide gene into the lymphocytes before infu-
sion and the use of lymphocytes that target either tumor-
specific antigens or minor histocompatibility antigens
expressed on tissues from which the tumor is derived.
Initial clinical experiences
Postgrafting MMF/cyclosporine as conditioning for patients
with severe T cell immunodeficiency. The hypothesis that
patients with severe T cell immunodeficiencies would not
require pretransplant conditioning is supported by recent
observations [56]. A 30-year-old male with a common vari-
able immunodeficiency, a history of recurrent serious infec-
tions, and active Mycobacterium avium infection received an
HSC transplant from his HLA-identical sibling without pre-
transplant TBI, but with postgrafting MMF/cyclosporine. At
3 months posttransplant, donor cells comprised 50% of bone
marrow cells, 90% of peripheral blood granulocytes, and
~95% of monocytes. The T cell count was >1000/µL, with
30% donor cells. Acute GVHD grade II developed and was
effectively treated with steroids and cyclosporine. Despite
this, infectious complications resolved, including bone mar-
row granulomas secondary to mycobacterial infection. Simi-
lar observations were made in a second patient with a T cell
immunodeficiency syndrome conditioned in the same way.
Low-dose TBI and MMF/cyclosporine as conditioning for
patients with hematologic malignancies. Based on results of the
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canine preclinical studies reviewed earlier, a clinical trial was
initiated to evaluate whether mixed chimerism can be estab-
lished using the approach developed in the dogs and used as
an immunologic platform for subsequent DLI to treat
underlying hematologic malignancy [57]. Patients were con-
ditioned with 200 cGy TBI followed by PBSC allografting
from HLA-identical siblings and then postgrafting immuno-
suppression with MMF/cyclosporine for 28 and 35 days,
respectively. The study targeted patients aged 50–75 years
old, a population for which allografting is used sparingly due
to the increased toxicities seen with increasing age. The goal
was to develop a nontoxic protocol that would allow allo-
grafting to be performed as an outpatient procedure. Initial
experience has confirmed the feasibility and safety of this
approach. Patients have experienced minimal nausea, vomit-
ing, diarrhea, and no alopecia, side effects almost invariably
associated with high-dose conditioning regimens, and
patients up to the age of 72 years have been transplanted in
an outpatient setting. Myelosuppression was mild, particu-
larly in patients with relatively normal counts pretransplant,
and in several cases no transfusion support was required. Of
the initial 26 patients studied, each has shown evidence of
donor engraftment with mixed chimerism sustained up to at
least 2 months posttransplant. Three patients rejected their
grafts between 60 and 90 days posttransplant and recovered
endogenous hematopoiesis. The first patient treated, who
had chronic lymphocytic leukemia, showed complete clear-
ing of leukemia and became PCR-negative for the tumor-
specific immunoglobulin gene rearrangement as determined
by assays at 7 and 10 months posttransplant. Although fol-
Table 3. Reduced-intensity nonmyeloablative conditioning regimens used in
treatment of malignancy
Regimen Reference
1. Fludarabine 30 mg/m2 3 4, cytosine arabinoside 2 g/m2 3 4, [58]
idarubicin 12 mg/m2 3 3
2. Fludarabine 30 mg/m2 3 4, melphalan 140 mg/m2 3 1 [58]
3. 2-Chlorodeoxyadenosine 12 mg/m2/d 3 5, [58]
cytosine arabinoside 1 g/m2 3 5
4. Fludarabine 30 mg/m2 3 3–5, cyclophosphamide 300 mg/m2 [59]
to 1000 mg/m2 3 1–2
5. Fludarabine 30 mg/m2 3 2, cytosine arabinoside [59]
500 mg/m2 3 2, cisplatin 25 mg/m2 3 4
6. Fludarabine 30 mg/m2 3 6, busulfan 4 mg/kg/d 3 2, [60]
antithymocyte globulin 10 mg/kg/d 3 4
7. Cyclophosphamide 50 mg/kg 3 4, ATG 3 3 or 4 [62]
pre- and posttransplant, ( thymic irradiation 7 Gy 3 1
8. Fludarabine 25 mg/m2 3 4, cyclophosphamide 60 mg/kg 3 2 [61]
Figure 3. Conceptual approach to clinical application of mixed chimerism
Microsatellite markers represent chimerism analysis of hematopoietic cell DNA using PCR and gel electrophoresis to identify donor and recipient specific bands.
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low-up is relatively short and conclusions cannot be drawn
as to overall therapeutic effectiveness, the ability to establish
allografts and GVL reactions has been documented.
Reduced dose conditioning regimens for allografting in patients
with malignancy. Several groups of investigators have report-
ed a more conventional approach to reducing regimen-relat-
ed toxicities. The approach involves the use of regimens of
lower intensity than typical high-dose conditioning regimens
aimed at suppressing both host malignancy and HVG reac-
tions. The regimens have been of varying intensity (Table 3)
and have involved either dose reduction of conventional
transplant agents or the use of modified conventional
chemotherapy regimens for specific diseases. PBSC grafts
were used in most of these transplants. Investigators specu-
lated that because of the reduced intensity of conditioning
regimens, mixed chimerism might result, and the regimen
could be followed as necessary by DLI. Many of the patients
treated with these approaches have been heavily pretreated, a
factor that may contribute to successful engraftment but may
also reduce the likelihood of stable mixed chimerism devel-
oping through suppressing recipient immunity.
Investigators from the M.D. Anderson Cancer Center
in Houston have based their conditioning programs on the
use of purine analogs, fludarabine or 2-chlorodeoxyadeno-
sine [58,59]. A multiplicity of regimens was used to provide
effective chemotherapy of underlying malignancy and to
facilitate donor cell engraftment. For example,
fludarabine/idarubicin/cytosine arabinoside was used in
patients with myeloid malignancies, whereas fludarabine/
cytosine arabinoside/platinum or fludarabine/cyclophos-
phamide was used in patients with lymphoid malignancies.
Of 15 patients with myeloid malignancies (median age 59
years), eight had donor cell engraftment documented in the
bone marrow within 30 days of transplant. Although one
patient achieved a sustained complete response that
appeared to be attributable to a GVH reaction, overall sur-
vival in this group was poor, no doubt in part because of the
advanced state of the patients’ underlying malignancies.
More encouraging results were reported in patients with
lymphoid malignancies, suggesting the responsiveness of
low-grade non-Hodgkins lymphoma and chronic lympho-
cytic leukemia to this approach. 
Slavin et al. [60] performed PBSC allografts in 26
patients using a regimen of fludarabine 30 mg/m2 3 6,
busulfan 8 mg/kg, and ATG 40 mg/kg. This study included
not only patients with malignancies, but also three patients
with b-thalassemia, Blackfan-Diamond anemia, and Gauch-
er disease. Compared with the Houston studies, patients had
less advanced malignancy and were younger (median age 31
years), and overall survival in the study was very good
(event-free survival 77.5% at 9 months). Nine of 26 patients
developed transient mixed chimerism and went on to
become full donor chimeras. Four patients died of GVHD,
however, which appeared due to the use of inadequate
GVHD prophylaxis in patients who had otherwise good-risk
hematologic disease, and clinical evidence of veno-occlusive
disease of the liver developed in 50% of the patients.
Others have reported using modifications of a fludara-
bine/cyclophosphamide combination [61] or high-dose
cyclophosphamide plus ATG with or without thymic irradi-
ation [62]. In those studies, the regimens were designed to
achieve both antitumor effects and engraftment leading to a
GVL effect. Severe GVHD was encountered in a significant
number of patients. Of note, engraftment was achieved in
HLA-mismatched transplants, resulting in mixed chimerism
and GVL effects [62]. 
Despite the use of nonmyeloablative conditioning, many
of these regimens are still quite toxic and some involve using
high-dose chemotherapy (e.g., 200 mg/kg cyclophos-
phamide). The busulfan regimen caused significant toxici-
ties, including veno-occlusive disease in 13 of 26 patients
treated [60]. Although many of the patients were pretreated,
the busulfan-based regimen did allow engraftment in seven
patients with CML and three patients with nonmalignant
disorders who presumably had not received prior therapy
that would have significantly diminished HVG reactions.
This, in turn, suggests that substantial dose reductions in
conventional conditioning regimens are possible without
exposing patients to a major risk of graft rejection when
using HLA-identical donors and PBSC as a source of stem
cells. With the exception of the fludarabine and low-dose
cytoxan regimen, these regimens appear too toxic to be used
routinely in an outpatient setting.
CONCLUSIONS AND FUTURE DIRECTIONS
Preclinical studies and results of initial preclinical studies
indicate that for many clinical circumstances pertaining to
the use of stem cell transplantation, currently used intensive
and toxic conditioning regimens may ultimately be replaced
by nonmyeloablative immunosuppression because allogeneic
stem cell grafts create their own space in the host’s bone
marrow. Immunosuppression delivered before transplant
may affect exclusively host cells, while immunosuppression
delivered after transplant can be used with the intent of
establishing mutual graft–host tolerance that would be mani-
fest as stable mixed chimerism. Observations that mixed
chimerism can be protective against GVHD suggest that the
establishment of mixed chimerism with low-dose condition-
ing should be a priority in the use of allografting in nonma-
lignant diseases compared with the induction of full donor
chimerism. In contrast, for patients with malignancy, the
goal is to establish full allogeneic donor chimerism through
either the initial PBSC graft or subsequent DLI. The latter
is attractive for the treatment of less aggressive diseases, such
as chronic myeloid and chronic lymphocytic leukemias, in
which establishing allografts without GVHD in an outpa-
tient setting would be a desirable initial step. This would
ultimately allow for development of DLI strategies that are
less toxic and more tumor specific. An improved toxicity pro-
file and lower cost of allografting would be critical to devel-
oping new strategies that target solid tumors. The applica-
tion of this approach to aggressive, rapidly growing malig-
nancies is somewhat problematic. Because GVL responses
may occur slowly, strategies to augment rapidly developing
and effective antitumor responses that do not result in over-
whelming GVHD are needed. While intensive chemo-
therapy has been used for this purpose to date, disease tar-
geting with monoclonal antibodies may have an important
future role in such circumstances.
Preclinical canine studies demonstrated the utility of
using low-dose TBI for establishing mixed chimerism and,
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in a disease model of PK deficiency, that the correction of
severe hemolytic anemia can be achieved through the estab-
lishment of mixed chimerism. This may have major implica-
tions for the treatment of diseases such as sickle cell anemia
and b-thalassemia. Because even the use of low doses of
irradiation may predispose to malignancy, the development
of newer, less toxic approaches to establishing donor-recipi-
ent tolerance are of continued importance. These may
include the use of T cell–specific monoclonal antibodies and
blockade of T cell costimulatory pathways such as a CD40-
CD154 and B7-CTLA4/CD28, which may further lead to
specific donor-host tolerance without impairing broader T
cell reactivity. Finally, initial promising results with attenu-
ated conditioning regimens have been achieved, primarily in
transplants with HLA-identical siblings. Achieving engraft-
ment with nontoxic regimens using related MHC-mis-
matched or unrelated MHC-matched donors may require
considerably more potent immunosuppression, both to pre-
vent rejection and to control GVHD.
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